Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Observer-blind, Controlled Trial to Assess the Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

NCT04984408 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT04984408
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04984408 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Observer-blind, Controlled Trial to Assess the Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Lead sponsor
International Vaccine Institute
Phase
Phase 3
Overall status
Unknown status
Start date
October 1, 2021
Completion date
September 30, 2024
Enrollment
8,825 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 disease